LOT 1 - 22,000 BT Ceftriaxone disodium for injection
About This Opportunity
TranslatedThis tender concerns Lot 1, specifically the procurement of 22,000 bottles of Ceftriaxone Sodium for Injection, totaling 60,000,000 units. This is part of a larger framework agreement (DBS) for pharmaceuticals. The stated quantities represent projected needs over the duration of the agreement, with specific forecasts for 2021. It is important to note that additional active ingredients may be procured through separate tenders. Furthermore, existing framework agreements for Antibiotics, Antidotes, Corticoids, Narcotics, Analgesics, and Anticoagulants, scheduled to end on December 31, 2021, are intended to be integrated into this current framework agreement effective January 1, 2022.
The tender also lists anticipated requirements for other drug categories. Under 'Cardiology,' specific items include Adenosine Injection (total need approx. 31,010 ampoules), Amlodipine Tablets (total need approx. 907,000 units), Cafedrine and Theodrenaline Hydrochloride Injection (total need approx. 111,002 ampoules), Candesartan Cilexetil Tablets (total need approx. 1,730,176 units), Metoprolol Succinate Extended-Release Tablets (total need approx. 481,540 units), Ramipril Tablets 2.5 mg (total need approx. 804,180 units), and Ramipril Tablets 10 mg (total need approx. 168,200 units).
Under 'Antiemetics,' requirements include Dimenhydrinate Injection (62 mg, total need approx. 31,220 ampoules), Dimenhydrinate Injection (100 mg with Benzyl Alcohol 105 mg, total need approx. 17,524 ampoules), Dimenhydrinate Tablets (50 mg, total need approx. 1,700,000 units), and Ondansetron Hyd...
This is a supplies contract in the health and medical services and general supplies sectors, with a focus on Pharmaceuticals and Medical Equipment. Located in Germany, Europe, this opportunity is open to firms and consortiums.
Published through TED - Tenders Electronic Daily (EU), a national government procurement portal. Public procurement tenders follow the country's national bidding regulations and may have specific eligibility and documentation requirements for the supply of goods in the health and medical services sector. Supply contracts typically require bidders to demonstrate product compliance with technical specifications, delivery capacity, and relevant certifications. This contract has already been awarded. The information is published for transparency and market intelligence purposes.
Description
Auto-translated from German60,000,000 units (Units) It is intended to contract the following medicines within the framework of the DBS, for example. The quantities indicated (total time = duration of the DBS; demand 2021 = estimated annual demand 2021) are forecast values. It is expressly pointed out that further active ingredients can be placed through individual tenders. Furthermore, it is planned to terminate the DBS Antibiotics and the DBS Antidotes, Corticoids, Narcotics, Analgesics and Anticoagulants prematurely on 31.12.2021 and to transfer them to the DBS in question on 01.01.2022 Legend: AM = Ampoule, EA = Piece, TU = Tube, BT = Bottle, TBL = Tablet, IE = International Unit Cardiacs 1. ADENOSINE INJECTION (Active ingredient ADENOSINE 6 MG/2ML), total demand approx. 31,010 AM, demand 2021 approx. 30,210 AM, 2. AMLODIPINE TABLET (Active ingredient AMLODIPINE 5 MG), total demand approx. 907,000 EA, demand 2021 approx. 2,400 EA, 3. CAFEDRINE AND THEODRENALINE HYDROCHLORIDE INJECTION (Active ingredient 1 CAFEDRINE 200 MG, Active ingredient 2 THEODRENALINE 10 MG), total demand approx. 111,002 AM, demand 2021 approx. 47,562 4. CANDESARTANCILEXETIL TABLETS (Active ingredient CANDESARTAN 16 MG divisible) total demand approx. 1,730,176 EA, demand 2021 approx. 0 EA 5. METOPROLOL SUCCINATE TABLETS WITH PROLONGED RELEASE (Active ingredient METOPROLOL 39.91 MG divisible) total demand approx. 481,540 EA, demand 2021 approx. 5,100 EA 6. RAMIPRIL TABLET (Active ingredient RAMIPRIL 2.5 MG), total demand approx. 804,180 EA, demand 2021 approx. 0 EA 7. RAMIPRIL TABLET (Active ingredient RAMIPRIL 10MG) total demand approx. 168,200 EA, demand 2021 approx. 3,600 EA Antiemetics 1. DIMENHYDRINATE INJECTION (Active ingredient DIMENHYDRINATE 62 MG), total demand approx. 31,220 AM, demand 2021 approx. 29,040 AM 2. DIMENHYDRINATE INJECTION (Active ingredient DIMENHYDRINATE 100 MG, Active ingredient 2 BENZYL ALCOHOL 105 MG) total demand approx. 17,524 AM, demand 2021 approx. 12,000 AM 3. DIMENHYDRINATE TABLETS (Active ingredient DIMENHYDRINATE 50 MG) total demand approx. 1,700,000 EA, demand 2021 approx. 1,940 EA 4. ONDANSETRON HYDROCHLORIDE INJECTION (Active ingredient ONDANSETRON 4 MG) total demand approx. 46,485 AM, demand 2021 approx. 12,025 AM Ophthalmics 1. ACETAZOLAMIDE TABLET (Active ingredient ACETAZOLAMIDE 250 MG) total demand approx. 93,930 EA, demand 2021 approx. 90,130 EA 2. DEXPANTHENOL OINTMENT (Active ingredient DEXPANTHENOL 50 MG) total demand approx. 157,132 TU, demand 2021 approx. 27,930 TU 3. SODIUM CHLORIDE SOLUTION (Active ingredient SODIUM CHLORIDE 4.5 GM) total demand approx. 19,848 BT, demand 2021 approx. 6,648 BT 4. OXYBUPROCAINE HYDROCHLORIDE EYE DROPS (Active ingredient OXYBUPROCAINE 4 MG) total demand approx. 24,513 BT, demand 2021 approx. 19,970 BT Dermatics 1. ACICLOVIR CREAM (Active ingredient ACICLOVIR 50 MG/G) total demand approx. 32,090 TU, demand 2021 approx. 522 TU 2. DEXPANTHENOL EYE AND NASAL OINTMENT (Active ingredient DEXPANTHENOL 50 MG/G) total demand approx. 157,132 TU, demand 2021 approx. 27,930 TU 3. FAT CREAM FOR THE TREATMENT OF SKIN CONDITIONS ON DRY SKIN (Active ingredient FATTY ACIDS, UNSATURATED 8.15 MG) total demand approx. 27,413 TU, demand 2021 approx. 2,040 TU 4. Miconazole nitrate _Flupredniden Cream (Active ingredient 1 MICONAZOLE 1 MG, Active ingredient 2 FLUPREDNIDEN 0.9 MG) total demand approx. 15,023 TU, demand 2021 approx. 4,890 TU Gastrointestinal Therapeutics 1. LOPERAMIDE HYDROCHLORIDE CAPSULE (Active ingredient LOPERAMIDE 1.860 MG) total demand approx. 851,473 EA, demand 2021 approx. 260,200 EA 2. MAGALDRATE SUSPENSION (Active ingredient MAGALDRATE 1600 MG) total demand approx. 198,570 BG, demand 2021 approx. 0 BG 3. PANTOPRAZOLE SODIUM TABLET (Active ingredient PANTOPRAZOLE SODIUM-1.5-HYDRATE 45.110 MG) total demand approx. 7,512,528 EA, demand 2021 approx. 46,020 EA 4. SIMETHICONE CHEWABLE TABLETS (Active ingredient DIMETHICONE 40 MG) total demand approx. 274,260 EA, demand 2021 approx. 0 EA Cold 1. CETYLPYRIDINIUM CHLORIDE AND BENZOCAINE LOZENGES (Active ingredient 1 CETYLPYRIDINIUM 1.4 MG, Active ingredient 2 BENZOCAINE 10 MG) total demand approx. 5,917,888 EA, demand 2021 approx. 24,480 EA 2. MYRTOL CAPSULES (Active ingredient MYRTOL 300 MG) total demand approx. 2,593,640 EA, demand 2021 approx. 48,400 EA 3. ACETYLCYSTEINE TABLET (Active ingredient ACETYLCYSTEINE 600 MG) total demand approx. 558,430 EA,...
Data provenance
This notice is sourced from TED - Tenders Electronic Daily (EU) and was originally published on March 11, 2025. Last refreshed 14 days ago. Original language: German. BidsFactory mirrors official procurement notices and links back to the source for full legal text.
About Bundesamt für Ausrüstung, Informationstechnik und Nutzung der Bundeswehr
Bundesamt für Ausrüstung, Informationstechnik und Nutzung der Bundeswehr has issued 273 procurement notices on BidsFactory, including 17 currently open and 161 awarded contracts. Activity concentrates in Security, Defense & Justice, Transport & Logistics, and General Supplies & Services. All notices are published for Germany. Notices are distributed via TED - Tenders Electronic Daily (EU) and DÖE Bekanntmachungsservice (Germany). Most recent publication: August 22, 2026.
Frequently asked questions about this tender
Where will the contract be performed?
The contract is for delivery in Germany. Foreign bidders should review local registration, taxation, and any in-country presence requirements before submitting.
How can I submit a bid?
Visit TED - Tenders Electronic Daily (EU) to access the full notice, required documents, and submission instructions provided by the contracting authority.
Is this tender still open?
No — the contract has already been awarded to Hikma Pharma GmbH. The award notice is archived on BidsFactory for transparency and market intelligence.
Who is the contracting authority?
This notice was issued by Bundesamt für Ausrüstung, Informationstechnik und Nutzung der Bundeswehr in Germany. The authority is responsible for evaluating bids, awarding the contract, and managing performance.
What type of contract is this?
This is a Supplies contract in the Health & Medical sector. The classification helps bidders match the opportunity to their qualifications and registered scope of supply.
Find tenders like this automatically
Set up alerts and filters that match your business — never miss a relevant opportunity again.